retatrutide ly3437943 parkinson's disease clinical trial LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to proof of concept: Cell Metabolism A Study of Retatrutide (LY3437943)

In a Phase 2 clinical trial published in 2023 in the New England Journal of Medicine (Jastreboff et al.), participants receiving the highest dose of retatrutide lost up to approximately 24% of their body weight over 48 weeks a notably greater reduction than observed with currently approved agents

Include supporting tests, imaging, and risk-benefit discussion

Over the past ten years, GLP-1 receptor agonists (GLP-1RAs) such as Ozempic, Wegovy, and Mounjaro have taken the pharmaceutical world by storm

How to Talk to Your Doctor About GLP-1 Weight Loss Drugs Be clear about the purpose

Inulin has shown protective and tumor-suppressive effects in most CRC studies, but other reports have indicated that inulin intake promotes CRC development

Vad r Retatrutide & HGH